Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial

BACKGROUND: NVA237 is a once-daily dry-powder formulation of the long-acting muscarinic antagonist glycopyrronium bromide in development for the treatment of chronic obstructive pulmonary disease (COPD). The glycopyrronium bromide in COPD airways clinical study 1 (GLOW1) evaluated the efficacy, safe...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: D'Urzo, Anthony, Ferguson, Gary T, van Noord, Jan A, Hirata, Kazuto, Martin, Carmen, Horton, Rachael, Lu, Yimeng, Banerji, Donald, Overend, Tim
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2011
Assuntos:
Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3266210/
https://ncbi.nlm.nih.gov/pubmed/22151296
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1465-9921-12-156
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares